Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei CNCM I-1572
- Development stage
- Preclinical
- Lead developer
- Alfasigma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Lactobacillus paracasei CNCM I-1572 (also known as Lacticaseibacillus paracasei CNCM I-1572 or L. casei DG) is a patented probiotic bacterial strain of human origin. Originally isolated from human feces, it is deposited at the Pasteur Institute in Paris under accession number CNCM I-1572 and redeposited at the DSMZ as DSM 34154. Developed by the Italian pharmaceutical company SOFAR and subsequently acquired by Alfasigma, this strain is widely commercialized under the brand name Enterolactis. L. paracasei CNCM I-1572 is designed to survive gastrointestinal transit, resist gastric acidity and bile salts, and temporarily colonize the human gut. It modulates the intestinal microbiota, reduces mucosal inflammation, and influences host immune responses. Clinical studies have evaluated its efficacy in managing gastrointestinal disorders such as irritable bowel syndrome (IBS), symptomatic uncomplicated diverticular disease (SUDD), and preventing recurrences of chronic bacterial prostatitis (CBP).
- Brand names
- BiotikEnterolactisEnterolactis PlusInnovia NectarL. casei DG
- Other names
- Lacticaseibacillus paracasei CNCM I-1572Lacticaseibacillus paracasei DGLactobacillus casei DGLactobacillus paracasei CNCM I-1572Lactobacillus paracasei DG
Beyond the preview
Go deeper on lactobacillus paracasei CNCM I-1572.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei CNCM I-1572.